NEW YORK, June 21, 2026, 4:50 p.m. EDT
Main points
- Achieve Life Sciences dropped 9.51% to $4.85 ahead of its June 20 FDA deadline. A rejection tied to manufacturing is already seen as likely.
- Unicycive Therapeutics fell 2.84% to $6.85. The FDA is now set to make a decision on June 29, after previously aiming for June 27.
- The two applications have manufacturing gates, not efficacy gates, but the liquidity they reported is about 39.7% and 31.2% of their implied equity values.
Achieve Life Sciences (NASDAQ: ACHV) dropped 9.51% to $4.85 in the latest U.S. session. The decline hit as its June 20 FDA target for cytisinicline arrived, with the company already flagging that a third-party manufacturing issue should trigger a Complete Response Letter. Unicycive Therapeutics (NASDAQ: UNCY) closed down 2.84% at $6.85, ahead of a pending FDA decision on oxylanthanum carbonate, also tied to third-party manufacturing compliance. Nasdaq stayed shut Friday for Juneteenth, so Thursday’s move is the last real cash signal. These price drops fit with traders pulling back ahead of FDA calls, not reacting to new trial data.
Weekend deadlines shook up the calendar. ACHV had a June 20 cutoff, which landed Saturday. No formal word yet from the FDA or the company. UNCY first set June 27, but now its SEC filing and the last quarter update both point to June 29, 2026. So, traders look at one missed decision and another window that officially ends next Monday.
“Highly volatile” fits both names. ACHV traded from $4.82 to $5.50 Thursday, posting a 14.1% move intraday, with 6.95 million shares trading. UNCY saw a $6.66 to $7.331 range, about a 10.1% swing, with volume near 1.48 million shares. The Monday open will be the first regular session for pricing any weekend regulatory news. Achieve Life Sciences, Inc.
Achieve has mostly spelled out what’s ahead with the FDA. An earlier third-party manufacturer was hit with an Official Action Indicated classification tied to broad current Good Manufacturing Practice shortcomings, though Achieve has said these weren’t linked to cytisinicline itself. Management is bracing for a CRL and aims to file again in the fourth quarter of 2026, switching to Adare Pharma as the lead manufacturer, with hopes to launch in the U.S. in the first half of 2027.
Cytisinicline’s clinical data isn’t the hang-up. In pooled Phase 3 results with over 1,600 people, 12 weeks on the drug got continuous abstinence in 32.4% of folks with prior varenicline or bupropion use, versus 6.0% on placebo. The odds ratio was 7.5. The market is now focused on how long and difficult fixing the manufacturing will be—efficacy isn’t the sticking point.
Here’s the balance-sheet math that’s often skipped. Achieve reported $29.3 million in cash and marketable securities as of March 31, together with estimated net proceeds of $168.6 million from its April financing. With 102.66 million shares outstanding as of May 12 and Thursday’s close at $4.85, Achieve’s implied equity stands near $497.9 million. The company’s total liquidity, $197.9 million, is about 39.7% of that figure. This is not an enterprise-value figure and does not factor in debt, liabilities, or warrant dilution.
UNCY looks like the simpler approval-or-denial setup. The last CRL flagged just one issue tied to a third-party manufacturing vendor, the company said in its SEC filing. Unicycive reported the FDA did not object to OLC’s preclinical, clinical or safety data. The firm resubmitted in December, calling it a six-month Class II response. OLC is meant to act as a phosphate binder with less pill burden for chronic kidney disease patients on dialysis.
Unicycive reported $57.1 million in cash, cash equivalents and marketable securities as of May 11. With 26.70 million shares as of May 12 and a $6.85 closing price, the implied equity value comes to about $182.9 million. That puts disclosed liquidity at roughly 31.2% of equity value. The difference with ACHV is not the eight-percentage-point gap. The key point is that Achieve’s likely CRL has been well-flagged, while UNCY is still waiting for an approval decision.
The bear case for both names sits with outsourced manufacturing. Achieve risks seeing its CRL ask for more fixes than just switching to Adare. That could delay the planned Q4 resubmission or push back a first-half 2027 launch. Unicycive says if it fails inspection or ends up rejected again, another filing could be needed and push the timeline out by six to 12 months. These are small biotechs, so news could send shares through stop-loss levels. Manufacturing sign-off, though, wouldn’t mean launch success, reimbursement, or profits.
The key info up next is how Achieve’s expected FDA letter is worded—especially if Adare’s proposed swap meets the mark—then if Unicycive’s manufacturing vendor gets FDA compliance by June 29, 2026.
Disclaimer: This article is for information only. It is not investment advice, or an offer or a recommendation to buy or sell any security. Moves in biotechnology stocks can be sharp around regulatory rulings. Anyone trading should do their own research and think about their financial situation and appetite for risk.
